09:34 AM EST - Tekmira Pharmaceuticals Corporation : announced today that, together with collaborators at the National Cancer Institute, it has published promising preclinical data in the prominent journal Cancer Research. The data stem from the use of small interfering RNA enabled by Tekmira's lipid nanoparticle technology in preclinical models of human hepatocellular carcinoma (HCC) or liver cancer. Tekmira Pharmaceuticals Corporation
shares T.TKM are trading up $.03 at $1.33.
